Literature DB >> 21612903

Device type and real-world effectiveness of asthma combination therapy: an observational study.

David Price1, Nicolas Roche, J Christian Virchow, Annie Burden, Muzammil Ali, Alison Chisholm, Amanda J Lee, Elizabeth V Hillyer, Julie von Ziegenweidt.   

Abstract

BACKGROUND: Selection of inhaler device type appears to influence real-world effectiveness of inhaled corticosteroids (ICS), but data are lacking on the role of inhaler device in ICS and long-acting β2-agonist (LABA) combination therapy for asthma.
METHODS: This retrospective matched cohort study compared 1-year asthma outcomes for UK patients initiating fixed-dose combination (FDC) fluticasone-salmeterol delivered by pressurised metered-dose inhaler (pMDI) versus dry powder inhaler (DPI). Patients with asthma aged 4-80 years receiving a first prescription for FDC fluticasone-salmeterol by pMDI or DPI were matched on baseline demographic and asthma severity measures. Co-primary outcomes were asthma control (a composite measure comprising no recorded hospital attendance for asthma, oral corticosteroids, or antibiotics for lower respiratory infection) and exacerbation rate.
RESULTS: Compared with the DPI cohort (n = 1567), patients in the pMDI cohort (n = 1567) had significantly greater odds of achieving asthma control during the outcome year (odds ratio [OR] 1.19; 95% confidence interval [CI] 1.01 to 1.40). Exacerbation rate was lower but not significantly in the pMDI cohort (adjusted rate ratio for pMDI cohort, 0.82; 95% CI 0.66 to 1.00). The odds of treatment success (defined as no exacerbations and no change in asthma therapy) was significantly greater in the pMDI cohort (OR 1.23; 95% CI, 1.07 to 1.42).
CONCLUSIONS: For UK primary care patients, pMDIs appear to achieve better asthma control outcomes than DPIs for delivery of FDC fluticasone-salmeterol. Pragmatic trials are needed to further investigate real-world outcomes with different inhaler devices for combination therapy.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21612903     DOI: 10.1016/j.rmed.2011.04.010

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  18 in total

Review 1.  Fluticasone Propionate/Salmeterol MDPI (AirDuo RespiClick®): A Review in Asthma.

Authors:  Julia Paik; Lesley J Scott; Roy A Pleasants
Journal:  Clin Drug Investig       Date:  2018-05       Impact factor: 2.859

2.  Enhanced alveo pulmonary deposition of nebulized ciclesonide for attenuating airways inflammations: a strategy to overcome metered dose inhaler drawbacks.

Authors:  Hanan M El-Laithy; Amal Youssef; Shereen S El-Husseney; Nesrine S El Sayed; Ahmed Maher
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

3.  Which inhaled corticosteroid and long-acting β-agonist combination is better in patients with moderate-to-severe asthma, a dry powder inhaler or a pressurized metered-dose inhaler?

Authors:  Masato Muraki; Kyuya Gose; Soichiro Hanada; Hirochiyo Sawaguchi; Yuji Tohda
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 4.  Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes.

Authors:  Omar Sharif Usmani; Federico Lavorini; Jonathan Marshall; William Christopher Nigel Dunlop; Louise Heron; Emily Farrington; Richard Dekhuijzen
Journal:  Respir Res       Date:  2018-01-16

5.  Utility and effectiveness of Symbicort® Turbuhaler® (oral inhalation containing budesonide and formoterol) in a patient with severe asthma after permanent tracheostomy.

Authors:  Kohhei Maeda; Masao Yamaguchi; Hiroyuki Nagase; Nobuhiro Yasuno; Fumio Itagaki; Machiko Watanabe
Journal:  J Pharm Health Care Sci       Date:  2018-09-10

Review 6.  COPD: the patient perspective.

Authors:  Paul W Jones; Henrik Watz; Emiel F M Wouters; Mario Cazzola
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-02-19

7.  Comparison of serious inhaler technique errors made by device-naïve patients using three different dry powder inhalers: a randomised, crossover, open-label study.

Authors:  Henry Chrystyn; David B Price; Mathieu Molimard; John Haughney; Sinthia Bosnic-Anticevich; Federico Lavorini; John Efthimiou; Dawn Shan; Erika Sims; Anne Burden; Catherine Hutton; Nicolas Roche
Journal:  BMC Pulm Med       Date:  2016-01-14       Impact factor: 3.317

8.  The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study.

Authors:  Rupert Jones; Jessica Martin; Vicky Thomas; Derek Skinner; Jonathan Marshall; Martina Stagno d'Alcontres; David Price
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-08-17

9.  Real-life effectiveness and safety of the inhalation suspension budesonide comparator vs the originator product for the treatment of patients with asthma: a historical cohort study using a US health claims database.

Authors:  David B Price; Eran Gefen; Gokul Gopalan; Cristiana Miglio; Rosie McDonald; Vicky Thomas; Simon Wan Yau Ming
Journal:  Pragmat Obs Res       Date:  2017-05-18

10.  A comparative analysis of errors in inhaler technique among COPD versus asthma patients.

Authors:  Birsen Ocakli; Ipek Ozmen; Eylem Acartürk Tunçay; Sinem Gungor; Hilal Altinoz; Nalan Adiguzel; Zafer Ali Sak; Gokay Gungor; Zuhal Karakurt; Peri Arbak
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.